Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Other Operating Expenses (2018 - 2025)

Akebia Therapeutics (AKBA) has disclosed Other Operating Expenses for 8 consecutive years, with $26.2 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses changed N/A to $26.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $27.8 million through Dec 2025, up 7904.32% year-over-year, with the annual reading at -$524000.0 for FY2023, N/A changed from the prior year.
  • Other Operating Expenses for Q4 2025 was $26.2 million at Akebia Therapeutics, up from $578000.0 in the prior quarter.
  • The five-year high for Other Operating Expenses was $35.1 million in Q2 2021, with the low at -$524000.0 in Q2 2023.
  • Average Other Operating Expenses over 5 years is $5.5 million, with a median of $579000.0 recorded in 2025.
  • The sharpest move saw Other Operating Expenses surged 6353.68% in 2021, then plummeted 62.14% in 2023.
  • Over 5 years, Other Operating Expenses stood at $1.0 million in 2021, then crashed by 56.37% to $449000.0 in 2022, then plummeted by 216.7% to -$524000.0 in 2023, then skyrocketed by 166.22% to $347000.0 in 2024, then soared by 7459.08% to $26.2 million in 2025.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at $26.2 million, $578000.0, and $580000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.